Advantages of IL-17 inhibitor, ixekizumab, in the treatment of severe psoriasis

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Real-World Efficacy and Safety of Ixekizumab in the Treatment of Psoriasis: A Case-Series from Indian Sub-Continent2026
2. 2Ixekizumab in dermatology: revisited2025
3. 3Long-term Safety and Efficacy of Ixekizumab in Patients With Moderate to Severe Psoriasis – a Systematic Review of Randomised Controlled Trials2025
4. 4Comparative Analysis of the Long-Term Real-World Efficacy of Interleukin-17 Inhibitors in a Cohort of Patients with Moderate-to-Severe Psoriasis Treated in Poland2025
5. 5Real-World Evidence for Ixekizumab in the Treatment of Psoriasis, Psoriatic Arthritis, and Axial Spondyloarthritis: Systematic Literature Review 2022–20232025 · 7 citations